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Abstract
Background An estimated 4·7 billion people worldwide live in regions with high potential for exposure to soil 
transmitted helminths, a group of intestinal parasites that include Ascaris lumbricoides, Trichuris trichiura and 
hookworms (Necator americanus and Ancylostoma spp), each of which can aﬀ ect the health and nutritional status of 
women smallholder farmers. The two aims of this double blind, prospective, randomised trial were to determine the 
prevalence and intensity of hookworm infection in this population and to test whether treatment with albendazole 
aﬀ ects women’s work capacity, as measured by aerobic ﬁ tness. 
Methods In March, 2014, participants from safe motherhood groups on Idjwi Island, South-Kivu Province and Kindu, 
Maniema Province were selected for inclusion in stage one of our trial. We measured prevalence and intensity of 
hookworm infection, haemoglobin concentrations, and recorded baseline demographic information. Between 
July, 2014, and February, 2015, stage two of the trial took place and participants from the Kindu group were randomly 
assigned to receive treatment with single dose albendazole, 400 mg, or a similar looking placebo tablet. Kindu 
participants completed an exercise tolerance test (a modiﬁ ed YMCA step test) and we used these results as a proxy 
metric for work capacity. Work capacity was deﬁ ned as the change in a participant’s heart rate before and after 3 mins 
of step testing. The step test was repeated 7 months after treatment. All women and their families were given 
albendazole at the end of the study. Participants, investigators, social workers, and ﬁ eld assistants remained unaware 
of treatment allocation during the trial. Primary outcome was change in work capacity from baseline to 7 months 
after treatment. This trial is registered in ClinicalTrials.gov (NCT02102321)
Findings Hookworm prevalence was 51% (75 of 146 women) on Idjwi Island and 50% (124 of 250) in Kindu, with 99% 
light intensity infections. 112 women were allocated treatment with albendazole and 113 were allocated placebo. 
Results of regression modelling showed an interactive eﬀ ect of hookworm status and treatment group relative to 
change in work capacity, after controlling for baseline resting pulse rate and participant age (p<0·002). Estimated 
marginal means for work capacity for four analysis groups (hookworm positive in placebo group, hookworm positive 
in treatment group, hookworm negative in placebo, hookworm negative in treatment) showed women who were 
hookworm positive and received treatment had increased work capacity after treatment (9·744 beats per minute 
decrease, 95% CI 6·42–13.07) whereas women who were hookworm positive and received placebo had no change in 
work capacity after treatment (a non-signiﬁ cant decrease of 0·034 beats per minute, –3·16 to –3·84). 
Interpretation Treatment with albendazole was associated with improved aerobic work capacity at 7 months after 
treatment. Given the modest cost of the intervention during mass drug distributions, the periodic deworming of 
women smallholder farmers warrants further study.
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